Background/Aims: The impact of Helicobacter pylori (H. pylori) eradication after endoscopic resection (ER) of early gastric cancer (EGC) has not been fully evaluated. We tried to find out the effect of H. pylori eradication therapy on the development of metachronous gastric cancers and changes in Cyclooxygenase-2 (COX-2) expression following attempts to eradicate H. pylori after ER of EGC. Materials and Methods: We eradicated H. pylori in the patients with EGC after ER. Biopsy samples were taken according to the follow-up schedules for surveillance after ER. Results: Fifty five patients were enrolled and finished the follow up schedules. Of the 55, 28 were successfully treated H. pylori infection, and the other 27 were failed eradication of H. pylori. The mean follow-up period was 60.8 months. Five in the H. pylori ongoing infection group developed metachronous gastric cancer, whereas no new gastric cancers were found in the 28 eradication group (P=0.023). COX-2 expression in the eradication group was significantly decreased (1.4±0.2, n=28), compared to that in H. pylori ongoing infection group (3.0±0.4, n=27, P=0.0001) after the follow-up. Conclusions: The eradication of H. pylori seems to have a preventative effect on the development of metachronous adenocarcinomas and a suppressive effect on COX-2 expression in the patients after ER for EGC. (Korean J Helicobacter Upper Gastrointest Res 2011;11:117-123)
INTRODUCTION
Despite its decreasing incidence over recent decades, gastric cancer is still the second leading cause of cancer-related deaths worldwide. 1 The development and progression of gastric cancer seem to result, in part, from the accumulation of multiple genetic alterations, which lead to oncogene overexpression and tumor suppressor loss. 2, 3 The most important single factor responsible for the development of gastric cancer is Helicobacter pylori (H.
pylori) infection, which affects more than 50% of the world's population. 4 The risk for developing gastric cancer in patients with H. pylori infection is about two-to six-fold increases in non-infection individuals, according to epidemiological studies. [5] [6] [7] When diagnosed at an advanced stage, gastric cancer is usually an incurable disease. However, resection of the tumor at an early stage can confer a relatively favorable prognosis.
Complete cures have been obtained in some early gastric cancers (EGC), especially with the use of endoscopic treatment modalities such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). 8, 9 The incidence of lymph node metastasis is 0.36% in mucosal gastric cancer patients who have no lymphatic invasion, no histological ulceration, and a tumor diameter of less than 30 mm. 10 After endoscopic resection (ER), the disease can recur in the stomach in two patterns, local recurrence or metachronous gastric cancers. Many metachronous gastric cancers are thought to be de novo cancers and may arise from the same high-risk background mucosa.
The relationship between metachronous recurrence and H. 
MATERIALS AND METHODS

Patients
The study was enrolled a total of 55 consecutive patients 
Immunohistochemistry for COX-2
A paraffin-embedded mucosal biopsy specimen was mounted on a silane-coated glass slide. Immunohistochemical staining was performed using antibodies specific for COX-2; the COX2
antibody was a monoclonal antibody raised in a mouse against a synthetic peptide corresponding to human COX-2, amino acids 580-598 (DAKO, Carpinteria, CA, USA). For immunostaining, the COX-2 antibody (diluted 1：100) was incubated with the sections for 1 h at 37 o C, using a microwave method.
The primary antibody was omitted as a negative control.
The immunoreactivity was recorded using semi-quantitative and subjective grading, considering both the intensity of staining and the number of immunoreactive cells. The intensity was ＞60%) . The staining index, which ranged from 0 to 9, was obtained by multiplying the score for staining intensity times the staining area.
Statistical analysis
All results are expressed as means±SEM. For statistical analysis, ANOVA single-factor analysis was performed. Differences were deemed significant when P＜0.05. The incidence of cancer in other regions was compared between the two groups using the χ 2 test and Student's t-test. All statistical computations were performed using SPSS v.10 (SPSS Inc., Chicago, IL, USA). However, metachronous gastric cancers were detected in other regions in five patients (18.5%) belonging to the ongoing in- Fig. 2 . COX-2 expression in the mucosa adjacent to the cancer. COX-2 expression in the adjacent mucosa was significantly lower in the eradication group than in the ongoing infection group at the last follow-up.
RESULTS
Fig. 3. Immunohistochemical staining for COX-2. (A) COX-2 expression is present in epithelial cells and inflammatory mononuclear cells of patients after endoscopic resection for early gastric cancer and before eradication of H. pylori (original magnification, ×100). (B) COX-2 expression significantly decreased after eradication of H. pylori (original magnification, ×100).
fection group; this was significantly higher than the occurrence in the eradication group (P=0.023, χ 2 test, Fig. 1 ). The metachronous gastric cancers were found in the five patients within 4 years of ER: two at 13-14 months, two at 36 months, and one at 48 months after ER. Each metachronous gastric cancer was less than 10 mm in size and was located in the mucosal layer ( Table 2 ).
In the eradication group, we analyzed the grade of gastritis in the pre-eradication period and that of last follow-up biopsies after H. pylori eradication. The neutrophil infiltration scores in the antrum and the corpus were markedly decreased (antrum: (Fig. 2, 3 ).
COX-2 expression of the mucosa adjacent to cancer tissue was high in the patients with metachronous gastric cancer compared to that in the patients without metachronous cancer of ongoing infection group (5.6±0.9 versus 2.5±2.0, P=0.003).
DISCUSSION
The intestinal type of gastric adenocarcinoma forms glandular structures that somewhat resemble the glands of the gastrointestinal tract. This type has glandular atrophy with IM in the background mucosa. 23 The second histological type, the dif- Mucosal COX-2 expression has been shown to continue in patients with IM, even after eradication of H. pylori infection. 26 Other investigators have found that patients with IM exhibited reduced COX-2 expression at 1 year after successful H. pylori eradication, compared to expression before eradication therapy.
27
Our results are consistent with the latter observation. Our cancer patients with high carcinogenic background mucosa, including IM, showed decreased carcinogenic potential of the mucosa at more than 3 years after H. pylori eradication. This is based on decreased COX2 expression and the regression of atrophy and corporal IM in our patients after H. pylori eradication.
Furthermore, newly developed metachronous early gastric cancers were detected only in the ongoing infection group.
Some studies have suggested that the suppression of COX-2 reduced tumor development. [28] [29] [30] Methods of suppressing COX-2 in gastric mucosa include the ingestion of probiotics and H. pylori eradication therapy for H. pylori-infected mucosa, in addition to COX-2 inhibitors. 20 However, the ability of these methods to actually suppress the incidence of gastric cancer development in high-risk patients remains controversial.
Helicobacter pylori infection plays an important role in gastric carcinogenesis, but the mechanism of COX-2 expression in In the study, the overall eradication rate of PPI triple therapy was 63.6% by intention-to-treat analysis. Our study also included the patients who did not complete the medicines for H.
pylori eradication on account of poor compliance or side effects. We also assumed that a lot of the patients with antibiotic resistance were enrolled in the study.
We found 5 patients with metachronous gastric cancer in the ongoing infection group. The rate of the metachronous gastric cancer was relatively high compared to previous study in Japan. 13 Most of previous studies were performed during only 3 years after ER. 13, 36 Three metachronous cancers of our study were observed at 36 months and 48 months after ER. Fukase's study showed that 167 patients of control group could be followed up at 3 years. The cumulative incidence of metachronous gastric cancer was 14.4% among the 167 patients. The cumulative incidence rate of the study is very similar to the rate of our study at 3 years after ER.
Limitations of our study include the involvement a relatively small number of patients. A randomized multicenter trial assessing the preventive effect of H. pylori eradication on occurrence of new gastric carcinomas after ER was published in Japan. 36 However, the results of this Japanese study showed a relatively short-term outcome during 3 years. In our study, we observed long-term suppression of the development of metachronous gastric adenocarcinomas and decreased COX-2 expression after H. pylori eradication therapy in the patients who underwent ER of EGC. Further studies on a larger scale may confirm the usefulness of H. pylori eradication therapy in these patients.
